Phosphodiesterase 5 Inhibitor [EPC]

135416 reported adverse events

Drugs of this class: TADALAFIL SILDENAFIL AVANAFIL MACITENTAN AND TADALAFIL VARDENAFIL HYDROCHLORIDE

These side effects are most commonly reported by patients taking drugs of the Phosphodiesterase 5 Inhibitor [EPC] class:

# Side effect Count
0 DYSPNOEA 16396
1 HEADACHE 13856
2 DIARRHOEA 10353
3 NAUSEA 8855
4 DEATH 8680
5 FATIGUE 8234
6 DRUG INEFFECTIVE 7337
7 DIZZINESS 7112
8 PNEUMONIA 5955
9 COUGH 5747
See all common reactions for Phosphodiesterase 5 Inhibitor [EPC]

Drugs of the Phosphodiesterase 5 Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 PULMONARY ARTERIAL HYPERTENSION 4240 0.2923
1 INFUSION SITE INFECTION 657 0.2825
2 PULMONARY ARTERIAL PRESSURE INCREASED 446 0.2736
3 RIGHT VENTRICULAR FAILURE 1820 0.2594
4 INFUSION SITE DISCHARGE 446 0.2541
5 CATHETER SITE ERYTHEMA 544 0.2540
6 OXYGEN CONSUMPTION INCREASED 530 0.2216
7 INFUSION SITE HAEMORRHAGE 661 0.2007
8 INFUSION SITE PAIN 2528 0.1960
9 INFUSION SITE ERYTHEMA 1501 0.1779
See all enriched reactions for Phosphodiesterase 5 Inhibitor [EPC]